FDA's Moheb Nasr Discusses QbD with Emil Ciurczak

Our intrepid contributing editor and editorial advisor, the NIR and PAT expert Emil CIurczak talked with Dr. Nasr about a variety of topics, including the potential impact of downsizings on pharma quality initiatives, FDA inspections in a high-tech future, and harmonization between FDA and EMEA regarding PAT.